PRIMARY STUDY
Peripheral Cannabinoid-1 Receptor Blockade Ameliorates Cystitis Severity
Key Findings: Administration of JD5037, which is a CB1R blocker, this study found improved symptoms of cyclophosphamide-induced cystitis in rats, suggesting further studies may lead to therapeutic uses of CB1R blockage in treatment.
Type of Study: Animal Study
Study Result: Positive
Study Location(s): Israel
Year of Pub: 2022
Cannabinoids Studied: Synthetic Cannabinoid (unspecified), Endocannabinoid (unspecified)
Phytocannabinoid Source: Unspecified
Receptors Studied: CB1
Dosage: CB1R antagonist, JD5037 (3 mg/kg)